Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has ...

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

Merck (NSE: PROR) KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a company with strong financial fundamentals and impressive revenue growth ...

SpringWorks Therapeutics (SWTX) ... Merck will pay $47 per share in cash for SpringWorks, representing an equity value of about $3.9 billion or an enterprise value of $3.4 billion, ...

After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a deal with an equity value of nearly $4 billion. The acquisition was ...

Summary. Merck KGaA agreed to acquire SpringWorks Therapeutics for $47 per share in cash or for $3.9 billion; the acquisition brings in drugs of OGSIVEO and GOMEKLI to big pharma's pipeline.

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said.. An announcement may come as soon as Monday, the people said, asking not to be ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 ...

Merck (NSE: PROR) KGaA, Darmstadt, Germany, has completed its acquisition of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a company with strong financial fundamentals and impressive revenue ...